Golvatinib is primarily used in the field of oncology as a potential therapeutic agent for treating various types of cancer. It functions as a dual inhibitor of c-Met and VEGFR2, which are key signaling pathways involved in tumor growth, angiogenesis, and metastasis. By targeting these pathways, it aims to disrupt the proliferation and survival of cancer cells, particularly in cases where these pathways are overactive or mutated. Clinical studies have explored its efficacy in cancers such as gastric, liver, and breast cancer, especially in patients with resistance to other treatments. Additionally, it is being investigated in combination therapies to enhance its anti-tumor effects and overcome drug resistance. Its role in inhibiting both c-Met and VEGFR2 makes it a promising candidate for addressing aggressive and advanced cancers.